Keros Therapeutics
KROS
KROS
125 hedge funds and large institutions have $948M invested in Keros Therapeutics in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more funds holding
Funds holding: 112 → 125 (+13)
1.51% more ownership
Funds ownership: 70.18% → 71.7% (+1.5%)
Holders
125
Holding in Top 10
4
Calls
$4.55M
Puts
$4K
Top Buyers
| 1 | +$29.4M | |
| 2 | +$20.6M | |
| 3 | +$20.6M | |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12.7M |
| 5 |
Alkeon Capital Management
New York
|
+$8.82M |
Top Sellers
| 1 | -$10.3M | |
| 2 | -$9.35M | |
| 3 | -$8.86M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$7M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.48M |